Davis Polk advised the underwriters in connection with an initial public offering of 7,359,998 shares of common stock of Aptinyx Inc., at $16.00 per share (which includes the exercise in full by the underwriters of their option to purchase up to 959,999 additional shares), for total gross proceeds of $117.8 million. Aptinyx Inc.’s common stock is traded on the NASDAQ Global Select Market under the symbol “APTX.”

Headquartered in Evanston, Illinois, Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx’s lead programs focus on targeting and modulating N-methyl-D-aspartate receptors, NMDArs, which are vital to normal and effective function of the brain and nervous system.

The Davis Polk corporate team included partner Deanna L. Kirkpatrick and associates Ferrell Maguire Keel and Jaryn S. Fields. The intellectual property and technology team included counsel David R. Bauer. Partner William A. Curran and associates Gil Savir and Christina L. Tacoronti provided tax advice. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post